Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

Oxaliplatin 180Capecitabine 174Fluorouracil 154Radiotherapy 107Leucovorin 107Irinotecan 93Bevacizumab 69Surgical Procedures, Operative 49Cetuximab 39Drug Therapy 38Radiation 35Neoadjuvant Therapy 33Folfox protocol 29Chemoradiotherapy 29XELOX 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 21Radiotherapy, Intensity-Modulated 19Surveys and Questionnaires 17Proctectomy 16Biopsy 16Early Intervention, Educational 14trifluridine tipiracil drug combination 12Panitumumab 12Floxuridine 12tislelizumab 11regorafenib 11Nivolumab 11Laparoscopy 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Rectal Neoplasms × Immunoglobulin G × Clear all
NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

City of Hope Medical Center

Phase 1/2 Active not recruiting
20 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡